. T cell engineering is predicated on methods to safely and effectively genetically modify human T cells, which became available in the mid-1990s. It enables instruction of T cells to recognize any antigen of interest -for example, a tumour antigen. Targeting may be achieved through the transfer of a physiological receptor for the antigen, which is known as the T cell receptor (TCR) 3, 4 , or artificial T cell-activating receptors, which encompass a diverse set of fusion receptors that we eventually grouped under the general term of chimeric antigen receptor (CAR) 5 . Emulating the TCR, the first chimeric receptors were designed to mimic T cell activation, a function that is sufficient to specify cytolysis, but not sufficient to direct a sustained, effective T cell response. Such activating receptors are now referred to as first-generation CARs 5 . To augment T cell function and extend T cell lifespan, a different kind of receptor had to be designed. Receptors providing both activating and co-stimulatory signals were designed to augment T cell function as well as redirect T cell specificity 5 . These second-generation CARs have recently yielded impressive clinical results in patients with B cell malignancies, especially acute lymphoblastic leukaemia (ALL) [6] [7] [8] [9] [10] [11] and B cell lymphomas [12] [13] [14] [15] . Here, we review the nature and biological effects of engineered co-stimulation in tumour-targeted T cells, focusing on the pharmacology of second-generation CARs. The best known to date are those that utilize the signalling domains of the co-stimulatory receptors CD28 or 4-1BB (also known as CD137 or TNFRSF9), fused to the cytoplasmic domain of the T cell-activating CD3ζ chain 16, 17 . Hereafter, we refer to these two categories of receptors as 28ζ and BBζ CARs.
Principles of T cell activation and CAR design
Physiological T cell responses are initiated by the TCR, which imparts antigen specificity and acts as the gatekeeper of T cell activation 18, 19 . TCR signalling is amplified and modulated by a series of receptors known as co-stimulatory receptors, the prototype of which is CD28 (REF. 20 ). In the absence of co-stimulation, primary TCR stimulation may fail to drive T cell proliferation beyond the G-G 1 phase of the cell cycle and render the T cell unresponsive -a state known as anergy 21 . Co-stimulation prevents anergy, as well as some forms of activation-induced cell death (AICD) and T cell exhaustion, although senescence will eventually limit T cell function and/or survival.
The first chimeric T cell-activating receptors were generated in the early 1990s after the ζ-chain of the CD3 complex was cloned 22 . As this T cell-specific chain lacks an extracellular domain, the groups of Weiss, Seed and Klausner fused it to the extracellular domain of the TCR co-receptors CD8 or CD4, or to CD25 (also known as interleukin-2 receptor subunit-α) (FIG. 1a) , to study its function in leukaemic T cells [23] [24] [25] . The crosslinking of these chimeric receptors induced Ca 2+ influx and other 
First-generation CARs
Chimeric antigen receptors (CARs) with an endodomain consisting of the cytoplasmic signalling domain of CD3ζ or the Fcγ receptor.
Second generation CARs
Chimeric antigen receptors (CARs) that include a single co-stimulatory element within the endoplasmic domain in cis with the activating CD3ζ domain.
Anergy
Rapidly acquired state of T cell unresponsiveness occurring after suboptimal activation via the T cell receptor in the absence of co-stimulation or in the presence of co-inhibitory molecules.
Activation-induced cell death
(AICD). Apoptosis occurring following T cell activation.
Exhaustion
Progressive hyporesponsiveness developed by T cells after repeated exposure to antigen.
Single-chain variable fragment
(scFv). Fusion protein consisting of the variable fragments of the immunoglobulin heavy and light chains, connected by a glycine or serine linker.
Chimeric co-stimulatory receptor
Fusion molecule coupling antigen specificity to T cell co-stimulatory signalling, without activating domains.
hallmarks of early T cell activation, thus establishing the physiological function of the ζ-chain and providing a road map for the design of T cell-activating receptors. The addition of a single-chain variable fragment (scFv) to these receptors (FIG. 1b) , as first reported by Eshhar et al. 26 , afforded binding to the hapten trinitrophenyl (TNP) and antigen-induced T cell activation. These fusion receptors were shown to redirect specificity and induce proliferation in T cell hybridomas and preactivated T cells, but not in naive cells 27, 28 . Transgenic mouse models later revealed that T cells expressing ζ-chain-based CARs only modestly delayed tumour progression in vivo, as they only produced low amounts of interferon-γ (IFNγ) and rapidly anergized 28, 29 . Having established methods for transduction of human T cells (based on γ-retroviral mediated gene transfer) 30 , we were able, for the first time, to test ζ-chain-based CARs in primary T lymphocytes. Although these receptors effectively mediated cytotoxicity, we found them to be unable to direct T cell expansion upon repeated exposure to antigen 31 . In earlier studies, we had demonstrated that costimulation can be provided to T cells through antigenspecific receptors termed chimeric co-stimulatory receptors (CCRs ; FIG. 1c) . A CD28-based CCR was shown to direct IL-2 synthesis and offset activation-induced apoptosis in human primary T cells 32 . Having thus validated the costimulatory signal in a relevant cell type, we then fused our CCR construct with a ζ-chain-based CAR (FIG. 1d) . For the first time, we were able to engineer human primary T cells such that they can expand upon repeated exposure to antigen 16 . Finney et al. 33 and Hombach et al. 34 reported on similar dual domain receptors, showing increased cytokine secretion induced by CARs containing a co-stimulatory signalling domain. Multiple co-stimulatory domains have since been introduced into CARs, the best known of which are those incorporating CD28 or 4-1BB signalling elements 16, 17 . These have both been utilized in patients with B cell malignancies. Here, we focus on the pharmacological properties afforded by these receptors, and also briefly summarize other second-generation CAR designs.
CD28 co-stimulation
The TCR alone is not sufficient to prime naive T cells to clonally expand and differentiate into effector and memory T cells. For a productive immune response to develop, T cell activation requires a concomitant co-stimulatory signal provided by CD28 (REFS 35, 36) . CD28 is a member of the immunoglobulin super family of co-stimulatory and inhibitory receptors, which also includes ICOS (inducible co-stimulator), BTLA (B-and T-lymphocyte attenuator), CTLA4 (cytotoxic T lymphocyte-associated antigen 4) and PD1 (programmed cell death protein 1) [37] [38] [39] [40] . CD28 is a 44 kD type I transmembrane protein, expressed as a glycosylated, disulfide-linked homodimer 41, 42 . It is expressed in 95% of human CD4 + T cells and 50% of CD8 + T cells 43 (unlike in the mouse where it is homogenously expressed on CD4 + and CD8 + T cells) 44 , as well as regulatory T cells (T Reg cells), plasma cells, neutrophils, eosinophils, and natural killer T (NKT) cells [45] [46] [47] [48] [49] . Together with the TCR, CD28 is recruited to microclusters in the immunological synapse that forms between T cells and antigen presenting cells (APCs). The main function of CD28 is to augment TCR signalling, resulting in increased cytokine production, clonal proliferation, differentiation and survival. In doing so, CD28 increases TCR sensitivity by lowering the thres hold TCR engagement that is required for efficient T cell activation 50 , enabling T cell responses against weak agonist peptides 51 . Although it was initially thought that CD28 may have its own signalling pathway, it is now known that CD28 essentially amplifies TCR signalling 52, 53 , which affects cytokine production 54, 55 , cell cycle progression 56 , apoptosis 57 , epigenetic structure 58 and metabolism 59, 60 . The cytoplasmic tail recruits the phosphoinositide 3-kinase (PI3K)-AKT pathway, which is important for cell proliferation, as well as the kinases PKCθ, LCK and RAS 20 . LCK and PKCθ recruitment induces Ca 2+ influx and activation of the transcription factor NFAT, resulting in upregulation of T-bet, a transcription factor that induces T helper 1 (T H 1) cytokine production 55 . This induces increased expression of the cytokines IL-2, IFNγ, IL-4 and the macrophage inflammatory protein MIP1α (also known as CCR1), as well as cytokine and chemokine receptors 52 . CD28 co-stimulation is crucial for the induction of IL-2 secretion 54 ; IL-2 secretion is induced by RAS signalling and is dependent on the adaptor protein growth factor receptor-bound protein 2 (GRB2) and the transcription factor AP-1 (REF. 61 ), as well as NFAT 20 . Additionally, CD28 induces chromatin remodelling via c-REL (a nuclear factor-κB (NF-κB)-family transcription factor) 62 , rendering the IL2 locus accessible and thereby allowing for a more rapid secondary T cell response 58, 63 . Similar changes are induced to other cytokine loci, including IL4 and IFNG
64
. Cell-cycle progression is enhanced via upregulation of the cell-cycle regulator cyclin-D, facilitating progression to late G 1 and S phases 56 . The energy and biosynthesis needs associated with T cell activation [65] [66] [67] require a metabolic switch from fatty acid, pyruvate and glutamine oxidation [68] [69] [70] to aerobic glycolysis and glutaminolysis. The recruitment of the PI3K-AKT pathway enhances the expression of glucose transporter 1 (GLUT1), the serine/threonine kinase mammalian target of rapamycin (mTOR) and the transcription factor MYC, as well as NFAT and the canonical NF-κB pathway 71 , facilitating the required metabolic switch. PI3K-AKT also induces the upregulation of the anti-apoptotic protein BCL-X L and inhibition of the tumour suppressor p73 (both in an NF-κB-dependent manner) 72, 73 . This, combined with inhibition of the expression of FASL, an apoptotic inducer, and reduction of the activation of cysteine protease caspase 8, enhances cell survival 74, 75 . Through extracellular signal-regulated kinase (ERK)-and JUN N-terminal kinase (JNK)-dependent upregulation of the co-stimulatory receptors ICOS, CD40 ligand (CD40L) and 4-1BB, CD28 facilitates a sustained secondary response [76] [77] [78] . Importantly, CD28 co-stimulation is not only required during T cell priming but also contributes to the expansion, cytolytic function, IL-2 production and cell cycle completion of memory T cells 79, 80 . CD28 signalling is regulated in several ways. First, activation of CD28 requires binding with its ligands -CD80 or CD86. Low levels of CD86 are constitutively expressed on B cells, dendritic cells (DCs), Langerhans cells, monocytes and activated CD4 + T cells, and they are upregulated upon activation, as is CD80 (REFS 81, 82) . Both ligands induce the same signalling cascades, although it has been suggested that CD86 has a greater role in initiation and CD80 in maintenance of immune responses 65, 81 . Second, after repeated TCR and CD28-CD80 stimulation, CTLA4 and TNF (tumour necrosis factor) downregulate CD28 [83] [84] [85] . However, stimulation through 4-1BB can reconstitute CD28 expression and promote T cell reactivation and IL-2 production 86, 87 . Third, CD28 signalling is inhibited via CTLA4 and PD1. Cell surface CTLA4 is induced upon T cell activation and is a high-affinity receptor for both CD80 and CD86. It inhibits CD28 signalling by competing for receptor binding as well as enhancing the internalization and degradation of CD28 and trans-endocytosis of CD80 and CD86 (REFS 85, (88) (89) (90) . PD1 expression is induced within 24 hours after TCR stimulation and induces T cell exhaustion through blockade of CD28-induced PI3K activity [91] [92] [93] .
Owing to the importance of CD28 in both T cell priming and memory responses, incorporation of CD28 signals into a second-generation CAR is thus a fundamental and logical way to amplify CAR signalling, promote T cell proliferation and persistence, and offset anergy.
4-1BB co-stimulation
Following T cell priming, a number of co-stimulatory receptors appear on the surface of T cells in order to sustain activation. This includes members of the TNF receptor superfamily (TNFRSF), such as OX40, CD27, CD30, herpesvirus entry mediator (HVEM) and 4-1BB 94 . 4-1BB is a type II transmembrane protein that was first found in activated lymphocytes [95] [96] [97] [98] . It is expressed on a variety of lymphoid cells [99] [100] [101] [102] , as well as some non-haematopoietic tissues 98, 103, 104 . Unbound 4-1BB is expressed as a 30 kD monomer on the T cell surface, which forms a trimeric complex upon binding to its ligand. 4-1BB ligand (4-1BBL) is expressed on activated APCs as well as on activated T cells [105] [106] [107] [108] [109] . 4-1BBL is distinct from the other members of the TNFR family by its three-bladed propeller-like structure + T cells 118, 119 . It enhances TCR signalling through tyrosine phosphorylation of the adaptor protein SLP76, the TCR signalling subunits CD3ε, CD3ζ and the tyrosine kinase LCK, as well as through the recruitment of PKCθ and the increase in intracellular Ca 2+ levels 116 . Signalling is mediated by TNF receptor-associated factor 1 (TRAF1), TRAF2 and TRAF3 . TRAF1 is essential for the activation of ERK, upregulation of BCL-X L and downregulation of the pro-apoptotic protein BIM 124 . Additionally, it restricts the activation of the non-canonical NF-κB pathway in the absence of co-stimulation by preventing activation of the NF-κB-inducing kinase (NIK), but enhances the canonical NF-κB pathway upon co-stimulation 125 . TRAF2 is essential for the activation of p38 mitogen-activated protein kinase (p38 MAPK) and induction of NF-κB-dependent activation of the anti-apoptotic mediators BCL-X L and BFL-1. It also induces cytokine production via the MAPK pathway, promoting T H 1 differentiation and cytokine production in CD4 + T cells 122, 126 . TRAF3 moderates activation through suppression of the noncanonical NF-κB pathway 127 . In both CD4 + and CD8 + T cells, 4-1BB induces cell cycle progression in an IL-2-independent manner via ERK1 or ERK2 and PI3K
and in an IL-2-dependent manner via the PI3K-AKT pathway 128 . 4-1BB signals are potentiated in the presence of CD28 signalling, but 4-1BB can still be upregulated in CD28 null CD8 + memory T cells, wherein it exerts CD28-independent co-stimulation [129] [130] [131] [132] . Similar to CD28 signalling, 4-1BB is able to induce telomerase activity, enhancing its levels after CD3 and CD28 stimulation, and inducing re-activation of CD28-unresponsive T cells 133 . 4-1BB signalling affects the size, quality and maintenance of the memory CD8 + T cell pool and T cell expansion upon secondary challenge [134] [135] [136] . 4-1BB can amplify T cell proliferation in both CD8 + and CD4 + T cells 113, 135 . Although 4-1BB-deficient mice and 4-1BBL-deficient mice do not show a defect in CD4:CD8 T cell ratios, 4-1BB-deficient mice have a reduced number of primary CD8 + T cells owing to reduced proliferation of naive cells 137, 138 , a reduced CD8 + T cell response and a reduced memory CD8 + pool 139, 140 . 4-1BB stimulation can rescue T cells from anergy and exhaustion, even after downregulation of CD28 (REFS 141, 142) . However, the timing of 4-1BB signalling is of great importance. 4-1BB activation early after viral infection can have a detrimental effect by inducing AICD through prolonged upregulation of TNF and FAS 101, 143 . The incorporation of 4-1BB signalling domains in second-generation CARs is therefore a logical choice to prevent anergy and to promote T cell proliferation and memory, with the anticipation of a greater effect on T cell maintenance than on functional activation relative to CD28. 28ζ and BBζ CARs -structure and signalling Whereas a large amount of biological data on CD28, 4-1BB and some other co-stimulatory receptors are available, less is known about the function of their costimulatory domains within CARs. It would be mistaken to extrapolate all of the physiological functions of natural receptors to CARs, for a number of reasons. First, the recruitment of these domains does not follow interactions with a single or sometimes two physiological ligands; instead, it varies depending on the level of antigen on the target cell, the level of expression of the CAR in the T cell, and the affinity of the CAR. There is also a temporal and spatial difference with the expression pattern of the natural receptors owing to the constitutive expression of the vector-encoded CAR and the covalent linkage of the co-stimulatory and activating domains. Furthermore, receptors such as 4-1BB are monomers that normally trimerize upon activation, but they are forced dimers in most CAR designs. Additionally, the nature of the synapse that second-generation CARs form with APCs may not be the same as TCR-centred synapses. Finally, CAR functionality is not solely determined by the cytoplasmic signalling domains, as other structural features may affect its overall function
. All in all, the pharmacology of recombinant co-stimulatory receptors is an emerging field in need of more experimentation. There are presently few data on CAR signalling or comprehensive comparisons between CARs. The initial characterization of any new CAR typically consists of functional in vitro assays, including measurements of antigen-specific cytotoxicity, antigen-induced proliferation and cytokine production. The most informative reports utilize primary cells, in an experimental setting that requires efficient and non-toxic T cell transduction, such as that afforded by γ-retroviral or lentiviral vectors. Studies in leukaemic cells or hybridomas are less dependable, given the profound genetic and functional alterations that affect the proliferation, apoptosis, differentiation and function of these cells. It should also be appreciated that CAR studies in primary T cell studies are most commonly re-stimulation studies, in so far that T cells are activated and go through S phase before transduction 144, 145 , such that the first activation through the CAR (in vitro as well as in vivo) is de facto a second stimulation.
Both 28ζ and BBζ CARs augment cytokine secretion relative to first-generation CARs 16, 17, 146 . Both induce T H 1 cytokines, including IL-2, IFNγ, TNF, and granulocyte-macrophage colony-stimulating factor (GM-CSF), although more briskly for 28ζ CARs and more slowly for BBζ CARs [147] [148] [149] [150] [151] [152] [153] [154] . T H 2 cytokines -including IL-4 and IL-10 -are also produced, with markedly lower levels induced by BBζ constructs 148, 154, 155 . 28ζ CARs elicit more IL-2, although it should be noted that the level of IL-2 production elicited by different 28ζ CARs varies, potentially exceeding or falling below that afforded by endogenous CD28 (REFS 16, 146) . IL-2 is a crucial cytokine for T cell function and adoptive cell therapy 156 . The effect of CAR-induced IL-2 secretion is complex. IL-2 promotes CAR T cell proliferation and sustains effector function, and it may also affect neighbouring cells such as NK cells or T Reg cells. T Reg cell recruitment, if it occurs, is undesirable, but 28ζ CAR T cells are less sensitive to T Reg cell inhibition via IL-10 and TGFβ than first-generation CAR T cells 157 . Furthermore, a modified CD28 domain reducing IL-2 production can partially restore the cytolytic function of 28ζ CAR T cells in the presence of T Reg cells without affecting IFNγ secretion and T cell proliferation 158 . T Reg resistance can also be achieved by providing IL-12 to 28ζ CAR T cells 159 or through constitutive AKT activity 160 . Limited biochemical information is available on the signalling cascades induced by CARs. In leukaemia cell lines, it was shown that second-generation constructs containing CD28, ICOS, OX40 or 4-1BB domains induced similar levels of tyrosine phosphorylation as did ζ-chain-only constructs 153 . Consistent with the known biology of CD28, 28ζ CARs induce signalling via NF-κB, AKT, ERK and NFAT, and induce T-bet, eomesodermin homolog (EOMES) and GATA3 (REF. 161 ). 28ζ CARs have been shown to activate the PI3K pathway more consistently than BBζ CARs 150, 153, 162 . A key factor in the specificity and safety of CAR T cells is their dependence on antigen stimulation to induce signalling. Some second-generation CARs have been reported to possess constitutive or tonic activity; for example, CD19-specific BBζ T cells showed increased proliferation in vitro and enhanced in vivo survival in the absence of antigen 148, 163 . This may be due in part to the unnatural dimeric 4-1BB structure, as TRAF recruitment is highly dependent on conformational changes to 4-1BB 164 . Tonic signalling has not been observed with CD28 CARs 16, 148 , although it may occur when the scFv fragments oligomerize and induce CAR clustering and downstream signalling 161 . Antigen-independent activation owing to scFv crosslinking can be reduced by the selection of an appropriate heavy/light chain orientation, hinge region or the use of ligand-derived binding moieties instead of an scFv. Well-designed CARs should retain antigen-dependent function and avoid the induction of exhaustion or anergy secondary to structural flaws resulting in inappropriate signalling 165, 166 .
Antitumour efficacy in preclinical models
Over a decade ago, we provided the first demonstration that CD19 CAR therapy utilizing human peripheral blood T cells can eradicate established lymphoma and leukaemia in immunodeficient mice 167 . In this study, the use of a first-generation CAR required a high T cell dose and optimized T cell expansion in the presence of CD28 co-stimulation and IL-15 (REF. 167 ). We later showed that a 28ζ CAR vastly outperformed a first-generation CAR in an aggressive ALL model 146 (and likewise in a syngeneic CD19 mouse model) 168 . An initial comparison of a 28ζ CAR and a BBζ CAR showed similar antitumour activity, albeit with higher accumulation of BBζ T cells, even after the tumour had been eradicated 147 .
The precise molecular basis of CAR-mediated tumour elimination has not been extensively documented. The antitumour effect of CAR T cells may be mediated by direct tumour cytolysis as well as cytokine secretion. Interestingly, direct cytolysis is not confined to CD8 + T cells, as CD4 + CAR T cells can also acquire strong cytolytic potential 167, 169 . IFNγ and TNF produced by CD4 + and CD8 + T cells are known to damage the tumour microvasculature and induce tumour cell cycle arrest and senescence [170] [171] [172] .
Complementing functionality, T cell persistence is another major determinant of antitumour activity. Both CD28 and 4-1BB co-stimulatory domains extend T cell survival compared to first-generation CARs 146, 148, 173 , albeit with different characteristics. 28ζ CARs programme higher functionality whereas BBζ CARs direct greater longevity. The mechanisms for the latter remain to be fully elucidated. Two studies showed a higher induction of the anti-apoptotic factor BCL-X L by 28ζ CARs compared to BBζ CARs, accompanied by reduced AICD 150, 152 , but in vitro BCL-X L induction may not directly correlate with in vivo persistence. Telomerase activity might also contribute to the differences in persistence. One study showed that a 28ζ CAR induced peak levels of telomerase 2 days after antigen stimulation, which declined by day 4, whereas a BBζ CAR induced more persistent activity 174 . Increased in vivo persistence of BBζ CAR T cells may also result from reduced exhaustion and apoptosis upon repeated antigen stimulation. For example, PD1 upregulation in T cells following CAR stimulation, combined with the induction of PD1 ligand 1 (PDL1) on tumour cells by IFNγ, might reduce T cell function and, ultimately, T cell longevity. Combined 28ζ CAR T cells and a PD1 blocking antibody thus enhance proliferative and functional T cell capacity in vitro and antitumour functionality in vivo, and are associated with reduced infiltration of myeloid derived suppressor cells 175 . It was also shown that engineered production of IL-15 by 28ζ CAR T cells (using a bicistronic vector inducing both CAR expression and IL-15 production) can lead to a reduction in PD1 expression and enhanced functionality 176 . The significance of PD1 expression, however, needs to be interpreted with caution. Among tumour-infiltrating T cells, PD1 + CD8 + T cells are potent tumour-reactive T cells that produce copious amounts of IFNγ and upregulate 4-1BB expression 177 . Nonetheless, the combination of PD1-PDL1 blockade with CAR T cell therapy, especially 28ζ CARs, is an attractive prospect.
CAR T cell functionality is commonly studied in bulk CD4 + and CD8 + T cells. Recent reports have shown that, in the context of 28ζ constructs designed to target mesothelin 169 or CD19 (REF. 178 ), CD4 + CAR T cells have a stronger expansion and higher cytokine secretion than CD8 + CAR T cells, and are more resistant to AICD. CD4 + CAR T cells alone may achieve tumour control and establish long-term persistence, and their presence enhances the antitumour activity of CD8 + CAR T cells 169 . The engineering of T cells at different stages of maturation is another important determinant of T cell anti tumour activity -a topic that is beyond the scope of this Review but has been recently reviewed elsewhere 179, 180 .
Box 1 | Structural features of chimeric antigen receptors
The functional properties of chimeric antigen receptors (CARs) are primarily determined by the signalling domains that are arrayed in the cytoplasmic tail. However, other structural components influence the overall signalling properties.
Binding moiety
The binding moiety, most commonly derived from an scFv or ligand, enables human leukocyte antigen (HLA)-independent antigen recognition. The affinity of the CAR for the antigen and the location of the epitope on the targeted antigen affect overall CAR function 221 . CAR affinity, along with CAR expression levels, will determine the antigen-binding characteristics of the CAR and the effectiveness of target cell recognition.
Hinge
The hinge or spacer domain provides a separation between the binding moiety and the T cell membrane. The requirement for a hinge is target dependent 222 . To establish an optimal effector-target inter-membrane distance, membrane-distal epitopes do not require a large hinge within the CAR; by contrast, membrane-proximal epitopes elicit suboptimal T cell activation in the absence of a hinge 223 . Longer flexible hinges also allow for better binding to relatively inaccessible epitopes 204, 224 . The hinge can also have detrimental effects. Cross-activation can occur between immunoglobulin G1 (IgG1) Fc-hinge-containing CAR T cells and Fcγ-receptor-positive (FcγR + ) cells, resulting in unspecific innate immune activation and activation-induced cell death (AICD) 222, 225 .
Transmembrane domain
The transmembrane domain is considered to be a purely structural requirement. Within first-generation CARs, CD4 and CD8 transmembrane domains allowed for similar cytokine secretion 226 . However, the CD3ζ transmembrane domain was shown to facilitate interaction between the CAR and endogenous CD3, allowing for heterodimerization with the endogenous T cell receptor (TCR), resulting in enhanced antitumour function and cytokine production 
4-1BB CD28
CD28 CD28
CD3ζ

Molecular remission
Complete remission and absence of disease based on PCR analysis.
Complete remission
Absence of disease based on imaging or biopsy analysis.
Severe cytokine release syndrome
A clinical syndrome comprising fever, hypotension, hypoxia and/or neurological symptoms, associated with cytokine release occurring following in vivo T cell activation.
In the clinic: the CD19 paradigm The most investigated target for CARs to date is CD19. We initially chose CD19 as a target for CAR-based therapy because of its common expression in most B cell leukaemias and lymphomas, and its absence in all normal tissues other than the B cell lineage 181, 182 . We provided the first proof of principle that CAR-modified human peripheral blood T cells targeted to CD19 can eradicate a broad range of B cell malignancies 167 . Successful B celltumour eradication was eventually obtained with different CD19 CARs 146, 148, 173, 183 , paving the way for numerous ongoing clinical trials. The targeting of CD19 eventually became a paradigm for evaluating CAR technology 184 . CD19 malignancies are so far the only setting where both 28ζ and BBζ CARs have been studied in the clinic.
Although the first clinical reports on the CD19 CAR trial focused on non-Hodgkin lymphoma (NHL) 15, [185] [186] [187] and chronic lymphocytic leukaemia (CLL) 6, [13] [14] [15] 188, 189 , the most dramatic results have been obtained in ALL [6] [7] [8] [9] [10] [11] . Three centres made seminal contributions to these clinical studies: the Memorial Sloan Kettering Cancer Center (MSKCC) for adult ALL, and the Children's Hospital of Philadelphia (CHOP) and the US National Cancer Institute (NCI) for childhood ALL. The first clinical results obtained with CAR therapy utilized the 19-28ζ CAR (FIG. 2) , which we transduced in autologous peripheral blood T cells collected by apheresis 7, 190 . Adult patients with relapsed, chemorefractory disease were infused with 3 million CAR + T cells per kg following a single infusion of cyclophosphamide (3 g per m 2 ) as conditioning. Four out of four patients with measurable disease went into molecular remission within 4 weeks 7 . Along with our group, the groups of Stephen Grupp and Crystal Mackall subsequently published follow-up studies in adult and paediatric disease [8] [9] [10] [11] . All three centres reported a highly remarkable complete remission rate -a rare occurrence for Phase I studies in oncology and especially for relapsed ALL. All reported the same two main toxicities: B cell aplasia, which is expected when targeting CD19 (REFS 146, 168) , and cytokine responses, sometimes causing severe cytokine release syndrome 8, 9, 191 . Similar toxicities have been seen with antibody therapies targeting co-stimulatory pathways
.
Although these studies follow overall similar steps (apheresis, retroviral CAR transduction, T cell infusion following chemotherapy conditioning), they differ in several regards, including in the CAR design (28ζ dualsignalling domain 16 utilized at the NCI and MSKCC, BBζ 17 utilized at CHOP ; FIG. 2) , T cell manufacturing, conditioning chemotherapy, patient age, tumour burden, tumour chemosensitivity, and T cell dosage 192 . It is striking that irrespective of these variances, the outcomes have been similar, which speaks to the extraordinary robustness of CD19 CAR therapy in ALL. However, the differences in procedures and patient characteristics, as well as the still low number of patients (approximately 74 in published studies and an estimated 150-200 infused at the time of this writing), makes it difficult to draw mechanistic conclusions at present. Some observations nonetheless emerge. CAR T cells traffic very effectively to the bone marrow, whether they express a 28ζ or BBζ CAR 9, 14 . They occasionally cause severe cytokine release, especially in patients with a higher tumour burden 7, 11 . A fever tends to start early on in recipients of 28ζ CAR T cells, and later in recipients of BBζ CAR T cells. BBζ CAR T cells may persist for many months in paediatric ALL patients 8, 11 , but less so in adults, in which persistence of 28ζ or BBζ CAR T cells is on the order of 1-3 months 9, 11 . More patients need to be studied in detail to better apprehend the function and persistence of CAR T cells in different patient populations.
One next frontier to explore is the activity of secondgeneration CARs against solid tumours. Such clinical studies are just starting in a handful of centres. Expectations notwithstanding, patience will be needed -several years -before sufficient data are gathered to evaluate the therapeutic potential of second-generation CARs in multiple tumour types.
Beyond 28ζ and BBζ CARs
It is unlikely that there is one universally optimal costimulatory domain for CAR-induced T cell activation. Optimal signals may differ in different T cell subsets, T cell differentiation stages or tumour microenvironments. Co-stimulation is a dynamic process to which multiple receptors contribute. Several of these have already been incorporated into CARs.
ICOS. Like CD28, ICOS is a member of the B7 family, although it is not expressed constitutively but upregulated following TCR-CD28 signalling. ICOS activates the PI3K-AKT pathway, but is unable to recruit GRB2 and LCK and therefore fails to induce strong IL-2 production. However, through activation of the transcription factor MAF, it induces higher secretion of 6, 7, 9 , consisting of an SJ25C1 single-chain variable fragment (scFv), CD28 spacer, transmembrane and signalling domain and CD3ζ chain 16 . b | CAR used in clinical trials at the US National Cancer Institute (NCI) 10 . This CAR contains the FMC63 scFv but is otherwise the same as the CAR shown in part a (from MSKCC). c | CAR used and developed by the Baylor College of Medicine team 188 . This CAR utilizes the FMC63 scFv, immunoglobulin G1 (IgG1) hinge, CD4 transmembrane domain, CD28 signalling domain and CD3ζ chain. d | Construct developed at St Jude Children's Research Hospital 17 and used by the teams at the Children's Hospital of Philadelphia and University of Pennsylvania 8, 11 . This CAR contains the FMC63 scFv, CD8α hinge, and 4-1BB signalling domain in tandem with the CD3ζ chain. + T cells 154, 193 and has a critical role in the induction of BCL-6, which is required for the transition from the effector to memory phenotype 36, 194 . ICOS deficiency affects T cell responses, resulting in reduced levels of effector T cells, memory T cells and T Reg cells, as well as diminished cytokine production [195] [196] [197] . ICOS has been incorporated in multiple second-generation CAR constructs, targeted at molecules such as CD33, the epidermal growth factor receptor variant III (EGFRvIII) or mesothelin 153, 154, 198 . ICOSζ CARs have higher PI3K activation and IFNγ production than BBζ CARs 153 . In T H 17 cells, ICOSζ CARs maintain a bipolar T H 17/T H 1 phenotype and secrete a distinct cytokine profile, including IL-17A, IL-17F and IL-22. In one study, the antitumour effect of the ICOSζ CAR was not greater than a 28ζ and BBζ CAR, although it resulted in greater persistence of CD4 + T cells 154 .
OX40. Like 4-1BB, OX40 is a member of the TNFRSF, and is expressed by activated T cells after TCR and CD28 stimulation. OX40 deficiency affects CD8 + T cell responses and reduces CD4 + T cell proliferation and effector differentiation 199, 200 . Its signalling is mediated by TRAF2, TRAF3 and TRAF5, inducing the canonical and non-canonical NF-κB pathways 201, 202 . OX40-based CARs targeting CD33 have been developed, and their characteristics appear to be overall similar to BBζ constructs in terms of proliferative support and cytokine secretion 153 . Numerous third-generation constructs incorporating OX40, targeting the ganglioside G D2 , mucin 1 (MUC1) or carcinoembryonic antigen (CEA) have been assessed 155, 203, 204 . CD27. CD27 is also a member of the TNFRSF, but one that is constitutively expressed by naive and memory T cells. Binding of TRAF2 or TRAF5 induces the canonical and non-canonical NF-κB pathways, as well as AP-1 downstream of the JNK-MAPK pathway 201 . CD27 stimulation results in IL-2, IFNγ and TNF production, as well as the upregulation of BCL-X L and memory formation. However, chronic CD27 signalling induces T cell apoptosis 201 . CD27 is able to induce T cell expansion in an IL-2-independent manner 205 and stimulates glycolysis, aiding the transition of naive and memory T cells to effector T cells 206 . Absence of CD27 results in reduced T cell expansion and impaired memory responses 134, 207 . The incorporation of CD27 into second-generation CARs targeting folate receptor-α induces T cell proliferation, BCL-X L expression and IFNγ production, displaying comparable in vivo efficacy with 28ζ and BBζ CARs in one study 151 .
NKG2D.
In a CAR design that does not utilize an scFv for antigen binding, NKG2D CARs utilize the NK cell receptor NKG2D to provide co-stimulation via interaction with the endogenous DAP10 co-signalling domain, providing PI3K-AKT stimulation and promoting a T H 1 response 208 . NKG2D ligands are expressed in a variety of tumour cells as well as normal tissues, especially in the context of inflammation 208, 209 . Different types of NKG2D-based CARs have been developed, using either the full length or the extracellular domain of NKG2D, combined with CD3ζ, CD28 and/or 4-1BB domains 210, 211 .
In vitro, the expression of NKG2D-based CARs in T or NK cells induces lysis of multiple tumour targets and displays a high capacity to secrete cytokines, including INFγ,
Box 2 | Co-stimulation targeted by monoclonal antibodies
Co-stimulatory pathways may be recruited to support T cell function via second-generation chimeric antigen receptors (CARs) or by using monoclonal antibodies (mAbs) that target co-stimulatory receptors 228 . These mAbs, which may exert agonistic or antagonistic effects, are potent modulators of tumour immunity. Like CAR T cells, they may also induce immune toxicities. The CD28 superagonist TGN1412 mAb activates T cells, bypassing T cell receptor (TCR) stimulation and other co-stimulatory signals. It may trigger massive cytokine release, known as a cytokine storm, which is associated with pulmonary infiltrates, acute lung injury, and acute renal failure, followed by disseminated intravascular coagulation 229 . The 4-1BB agonist mAb BMS-663513 has been tested in patients with solid tumours. Objective responses were observed in 17% of patients with melanoma and 14% of patients with renal cell carcinoma at low doses, but high doses may cause liver toxicity or fatalities [230] [231] [232] . Agonists of OX40 and CD40 are under investigation for multiple tumours, inducing potent responses, with occasional grade 3-4 toxicity [232] [233] [234] [235] [236] [237] . Trials investigating targeting of CD27 and gluco corticoid-induced TNFR-related protein (GITR) are ongoing.
Immune checkpoint blockade using antagonists against cytotoxic T lymphocyteassociated antigen 4 (CTLA4; ipilimumab) and programmed cell death protein 1 (PD1; pembrolizumab) has been approved by the US Food and Drug Administration (FDA). The best results have been seen in metastatic melanoma, where anti-CTLA4 treatment increases 3-year survival rates to 20%, and anti-PD1 treatment results in 32-38% overall responses 238, 239 . Targeting of the PD1-PDL1 axis can also be achieved through blocking of PDL1. In a variety of solid tumours, 6-17% overall survival was achieved 240 . Several additional anti-CTLA4, anti-PD1 and anti-PDL1 (PD1 ligand 1) trials are ongoing. Immune checkpoint blockade is also associated with occasional immune-related adverse events. This includes fatigue, rash, dermatitis, uveitis, neurotoxicity, hepatotoxicity, pancreatitis, nephritis and pneumonitis. Rare fatalities owing to anti-CTLA4-induced enterocolitis, colonic perforation, hepatotoxicity and cardiac arrests have been reported 239, 241 . Fatal pneumonitis has also resulted from anti-PD1 treatment 242 . These outcomes underscore the potency and enormous potential of targeting co-stimulatory pathways to augment tumour immunity and the need, whether using CAR T cells or mAbs, to tame and carefully manage these powerful drugs.
Third-generation CARs
Chimeric antigen receptors (CARs) containing two co-stimulatory elements within the cytoplasmic domain in cis with the activating CD3ζ domain.
TNF and GM-CSF. In vivo, full-length NKG2D-CD3ζ CARs provide a better immune response than T cells transduced with NKG2D alone 212, 213 .
Combinatorial strategies. Co-stimulatory signalling domains may be combined, either in cis (third-generation CARs) or in trans (combined CAR and CCR expression). Briefly, third-generation CARs incorporate two costimulatory domains within their cytoplasmic tail. Most commonly, CD28 and 4-1BB domains [147] [148] [149] [150] 152, 214, 215 or CD28 and OX40 domains 155, 203, 204 have been combined. Third-generation CARs showed similar or improved in vitro and in vivo cytolytic function compared to other CARs. Cytokine production levels vary in comparison with second-generation CARs, with both increased and decreased production levels reported 148, 150 . T cell proliferation and in vivo persistence may be increased in some cases 147, 150, 214 . Few clinical trials have utilized third-generation CARs to date. These did not suggest a clinical advantage over second-generation CARs 216, 217 . When combining co-stimulation in trans through two independent antigenspecific receptors such as a CCR and a CAR 32, 218 , two antigens are targeted: for example, ERBB2 and MUC1 (REF. 219 ); prostate-specific membrane antigen (PSMA) and prostate stem cell antigen (PSCA) 218 ; and mesothelin and α-folate receptor 220 . Dual antigen targeting may be used to enhance tumour targeting 219, 220 or reinforce tumour selectivity 218 .
Conclusions
CARs that incorporate co-stimulatory domains are conceptually distinct from those that only elicit T cell activation. The latter effectively redirect cytotoxicity, but dual-signalling CARs further reprogramme T cell function and T cell persistence. These second-generation CARs have recently yielded exciting clinical results in patients with B cell malignancies. Although more needs to be learned about the molecular functions of these CARs, both 28ζ and BBζ CARs have yielded high complete remission rates in B cell malignancies, especially ALL. Emerging data, albeit still incomplete, suggest that 28ζ CARs provide a brisker proliferative response and more vigorous activation of effector functions than BBζ CARs. The latter, however, persist longer and achieve comparable antitumour responses over a more protracted time period. This suggests that BBζ CAR T cells compensate for their lower functional potency by gradually building up and sustaining their numbers. These different kinetics may be exploited in different ways to further enhance the efficacy of CAR T cells and tailor CAR therapy to the requirements of different tumour burdens and tumour microenvironments. More studies are needed to better understand CAR function in different T cell types and to adjust CAR signalling to balance its effects on T cell function and persistence. A new field of immunopharmacology is born. 
